QQQ   437.60 (+0.24%)
AAPL   182.63 (+0.81%)
MSFT   407.48 (-0.01%)
META   487.05 (+1.10%)
GOOGL   138.88 (+0.95%)
AMZN   173.54 (-0.68%)
TSLA   199.73 (+0.17%)
NVDA   787.01 (-0.49%)
NIO   5.78 (+2.30%)
AMD   178.00 (+1.13%)
BABA   77.68 (+1.53%)
T   16.84 (+1.39%)
F   12.01 (+0.50%)
MU   91.85 (+2.67%)
CGC   3.53 (+1.73%)
GE   153.99 (-0.50%)
DIS   109.45 (+1.64%)
AMC   4.81 (+7.86%)
PFE   26.89 (-1.07%)
PYPL   60.16 (+1.40%)
XOM   104.03 (-0.21%)
QQQ   437.60 (+0.24%)
AAPL   182.63 (+0.81%)
MSFT   407.48 (-0.01%)
META   487.05 (+1.10%)
GOOGL   138.88 (+0.95%)
AMZN   173.54 (-0.68%)
TSLA   199.73 (+0.17%)
NVDA   787.01 (-0.49%)
NIO   5.78 (+2.30%)
AMD   178.00 (+1.13%)
BABA   77.68 (+1.53%)
T   16.84 (+1.39%)
F   12.01 (+0.50%)
MU   91.85 (+2.67%)
CGC   3.53 (+1.73%)
GE   153.99 (-0.50%)
DIS   109.45 (+1.64%)
AMC   4.81 (+7.86%)
PFE   26.89 (-1.07%)
PYPL   60.16 (+1.40%)
XOM   104.03 (-0.21%)
QQQ   437.60 (+0.24%)
AAPL   182.63 (+0.81%)
MSFT   407.48 (-0.01%)
META   487.05 (+1.10%)
GOOGL   138.88 (+0.95%)
AMZN   173.54 (-0.68%)
TSLA   199.73 (+0.17%)
NVDA   787.01 (-0.49%)
NIO   5.78 (+2.30%)
AMD   178.00 (+1.13%)
BABA   77.68 (+1.53%)
T   16.84 (+1.39%)
F   12.01 (+0.50%)
MU   91.85 (+2.67%)
CGC   3.53 (+1.73%)
GE   153.99 (-0.50%)
DIS   109.45 (+1.64%)
AMC   4.81 (+7.86%)
PFE   26.89 (-1.07%)
PYPL   60.16 (+1.40%)
XOM   104.03 (-0.21%)
QQQ   437.60 (+0.24%)
AAPL   182.63 (+0.81%)
MSFT   407.48 (-0.01%)
META   487.05 (+1.10%)
GOOGL   138.88 (+0.95%)
AMZN   173.54 (-0.68%)
TSLA   199.73 (+0.17%)
NVDA   787.01 (-0.49%)
NIO   5.78 (+2.30%)
AMD   178.00 (+1.13%)
BABA   77.68 (+1.53%)
T   16.84 (+1.39%)
F   12.01 (+0.50%)
MU   91.85 (+2.67%)
CGC   3.53 (+1.73%)
GE   153.99 (-0.50%)
DIS   109.45 (+1.64%)
AMC   4.81 (+7.86%)
PFE   26.89 (-1.07%)
PYPL   60.16 (+1.40%)
XOM   104.03 (-0.21%)
NASDAQ:PRE

Prenetics Global (PRE) Stock Price, News & Analysis

$4.85
-0.08 (-1.62%)
(As of 02/27/2024 ET)
Today's Range
$4.81
$5.08
50-Day Range
$4.36
$5.94
52-Week Range
$3.84
$18.15
Volume
99,588 shs
Average Volume
28,516 shs
Market Capitalization
$44.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$60.00

Prenetics Global MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,137.1% Upside
$60.00 Price Target
Short Interest
Healthy
0.10% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Prenetics Global in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.40) to ($0.40) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.67 out of 5 stars

Medical Sector

672nd out of 945 stocks

Holding & Other Investment Offices Industry

7th out of 11 stocks


PRE stock logo

About Prenetics Global Stock (NASDAQ:PRE)

Prenetics Global Limited operates as a diagnostics and genetic testing company in Hong Kong and the United Kingdom. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring device that offers COVID-19 testing solutions for professional use and home use. The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; ACTOnco, a comprehensive test that helps clinicians choose the optimal treatment for all major solid tumors; ACTDrug+, a screening test that checks for 40 cancer genes to map drug options and provide treatment strategy options; ACTLung, a test focused on biomarkers associated with lung cancer for targeted therapy; ACTFusion, a test that decodes 13 fusion genes and more than 350 transcripts to map drug options; and ACTCerebra, a genomic profiling service for solid tumors. It also offers ACTMonitor, a test that analyzes 50 forms of circulating tumor DNA in the bloodstream; and ACT Risk, a screening of 67 cancer genes associated with 9 common hereditary cancers and 11 cancer syndromes. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.

PRE Stock Price History

PRE Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Prenetics Global (PRE) Earnings Dates & Reports
PRENW Prenetics Global Limited WT EXP 051827
Prenetics Global Stock (NASDAQ:PRE) Insider Trades
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Prenetics Global: Q3 Earnings Insights
Prenetics Announces Third Quarter 2023 Financial Results
Prenetics Global Limited (NASDAQ:PRE): Is Breakeven Near?
Prenetics Global Ltd Class A PRE
Prenetics Global Limited Announces Reverse Stock Split
Prenetics Global Limited - Ordinary Shares - Class A
Prenetics Announces Second Quarter 2023 Financial Results
PRE - Prenetics Global Limited
Prenetics Global (NASDAQ: PRE)
See More Headlines
Receive PRE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prenetics Global and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
9/15/2023
Today
2/27/2024
Next Earnings (Estimated)
3/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Holding & other investment offices
Sub-Industry
N/A
Current Symbol
NASDAQ:PRE
Fax
N/A
Employees
400
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$60.00
High Stock Price Target
$60.00
Low Stock Price Target
$60.00
Potential Upside/Downside
+1,104.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-190,450,000.00
Pretax Margin
-29.55%

Debt

Sales & Book Value

Annual Sales
$275.76 million
Book Value
$26.27 per share

Miscellaneous

Free Float
N/A
Market Cap
$45.52 million
Optionable
Not Optionable
Beta
-0.11
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Sheng Wu Yeung (Age 45)
    Co-Founder & CEO
  • Dr. Chi Hung Tzang Ph.D. (Age 49)
    Co-Founder, Chief Scientific Officer & Member of Scientific Advisory Board
  • Mr. Hoi Chun Lo (Age 39)
    Chief Financial Officer
  • Dr. Yung Ho Wong DPHIL (Age 42)
    Chief Technology Officer
  • Ms. Yvonne L. Wong
    Chief Corporate Development Officer
  • Ms. Samantha Kwok
    Vice President People & Culture
  • Dr. Senthil Sundaram M.D. (Age 50)
    Chief Clinical Officer
  • Mr. Avrom Boris Lasarow (Age 47)
    Chief Executive Officer of EMEA
  • Dr. Shih-Chang Ong M.D. (Age 46)
    Chief Medical Officer & Member of Scientific Advisory Board
  • Mr. Joel Neoh
    Chief Consumer Officer & MD for CircleDNA














PRE Stock Analysis - Frequently Asked Questions

Should I buy or sell Prenetics Global stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Prenetics Global in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PRE shares.
View PRE analyst ratings
or view top-rated stocks.

What is Prenetics Global's stock price target for 2024?

1 Wall Street research analysts have issued 1 year price objectives for Prenetics Global's stock. Their PRE share price targets range from $60.00 to $60.00. On average, they expect the company's share price to reach $60.00 in the next twelve months. This suggests a possible upside of 1,137.1% from the stock's current price.
View analysts price targets for PRE
or view top-rated stocks among Wall Street analysts.

How have PRE shares performed in 2024?

Prenetics Global's stock was trading at $5.91 at the beginning of 2024. Since then, PRE shares have decreased by 17.9% and is now trading at $4.85.
View the best growth stocks for 2024 here
.

When is Prenetics Global's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 12th 2024.
View our PRE earnings forecast
.

How were Prenetics Global's earnings last quarter?

Prenetics Global Limited (NASDAQ:PRE) announced its earnings results on Friday, September, 15th. The company reported ($0.75) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.15. The firm earned $5.70 million during the quarter. Prenetics Global had a negative net margin of 55.31% and a negative trailing twelve-month return on equity of 3.89%.

When did Prenetics Global's stock split?

Prenetics Global shares reverse split on the morning of Tuesday, November 14th 2023. The 1-15 reverse split was announced on Wednesday, November 1st 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, November 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Who are Prenetics Global's major shareholders?

Prenetics Global's stock is owned by many different institutional and retail investors. Top institutional investors include Prudential PLC (7.49%), Aspex Management HK Ltd (3.79%) and Nomura Holdings Inc. (2.12%).

How do I buy shares of Prenetics Global?

Shares of PRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PRE) was last updated on 2/27/2024 by MarketBeat.com Staff